Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Endorecherche claims EM-800 for estrogen-dependent disorders

Oct. 11, 1996

Schering AG's tubulin polymerization inhibitors for cancer

Oct. 11, 1996

Daiichi claims new taxol derivatives

Oct. 11, 1996

Orphan drug status granted for camptothecin derivative

Oct. 11, 1996

Pierre Fabre discloses topoisomerase II inhibitors

Oct. 11, 1996

Nippon Kayaku evaluates novel doxorubicin preparation

Oct. 11, 1996

Antitumor antibiotics from the Kitasato Institute

Oct. 11, 1996

FK-317, a new antitumor antibiotic from Fujisawa

Oct. 11, 1996

U.S. Bioscience and Schering-Plough revise Ethyol agreement

Oct. 4, 1996

VX-853 for MDR reversal receives patent coverage

Oct. 4, 1996

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 14, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...